Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Acupuncture, Conventional care.
- Who it may be relevant to
- Registry conditions: Chemotherapy-Induced Nausea and Vomiting (CINV), Hematopoietic Stem Cell Transplantation (HSCT). Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Study and Mechanism Exploration of Acupuncture at Neiguan (PC6) for Preventing Nausea and Vomiting in Patients Undergoing Hematopoietic Stem Cell Transplantation
Overview
This study is testing whether acupuncture at a point on the wrist called "Neiguan" can help reduce nausea and vomiting in patients undergoing stem cell transplantation. Participants will receive either real acupuncture or standard care. We hope to find a safe way to improve comfort during cancer treatment.
Interventions
- Procedure Acupuncture
Add-on manual acupuncture at bilateral Neiguan (PC6) to standard quadruple anti-emetic prophylaxis. Disposable sterile acupuncture needles inserted perpendicularly 0.5-1 cun (approximately 10-25 mm) into Neiguan with even reinforcing-reducing manipulation; needles retained for 30 minutes. Administered once daily throughout the conditioning (preparative) regimen. This distinguishes the intervention from: (1) the active comparator arm in this study, which receives identical pharmacological prophy - Drug Conventional care
Standard quadruple pharmacological anti-emetic prophylaxis comprising a 5-HT3 receptor antagonist, an NK-1 receptor antagonist, dexamethasone, and olanzapine, administered per institutional HSCT supportive care protocol. No acupuncture or sham procedure is provided. This distinguishes the arm from the experimental arm, which receives the identical pharmacological regimen plus add-on manual acupuncture at Neiguan (PC6).
Primary outcome measures
- Incidence and severity of nausea and vomiting during the conditioning regimen for hematopoietic stem cell transplantation [Time frame: Throughout the conditioning period (approximately 3-7 days)]
Secondary outcome measures (1)
- Nutritional status assessed by serum albumin and prealbumin levels [Time frame: Baseline (pre-conditioning), Day 7, Day14, and Day 28 of conditioning, and Day 30 post-transplant]
Eligibility criteria
Inclusion criteria
Age 18-65 years, either sex. Patients scheduled to receive a conditioning (preparative) regimen for hematopoietic stem cell transplantation (HSCT).
Life expectancy ≥ 3 months. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment.
Voluntary participation with signed informed consent.
Exclusion criteria
Received chemotherapy with highly emetogenic agents within 14 days prior to enrollment.
Received radiotherapy within 7 days prior to enrollment, or planned radiotherapy during the study period.
Known hypersensitivity to any study drug or its excipients. Complicated with gastrointestinal obstruction, brain metastasis with symptoms of increased intracranial pressure, or any other condition that may cause and/or exacerbate nausea and vomiting.
Active infection. Unable to take oral medications. Use of any anti-emetic medication (including corticosteroids) within 48 hours or 5 half-lives of the drug (whichever is longer) prior to enrollment.
Any episode of nausea, vomiting, or retching within 24 hours prior to the first administration.
Severe psychiatric illness or cognitive impairment that precludes understanding, reading, and completing patient diaries.
Any other condition that the investigator deems would make the patient unsuitable for participation in this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Supportive care
Study locations
China · 1 center
- The General Hospital of Western Theater Command — Chengdu
Identifiers
NCT: NCT07747194 · PC6-HSCT